Chronic lymphocytic leukaemia trials in Canada

In Canada 23 Also abroad 308

23 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Where
Greenfield Park, Kingston, Moncton, Sherbrooke
Age
18 years and over
People
735 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00
Phase 3Taking people
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Where
Halifax, Montreal, Oshawa, Ottawa, Regina, Saint John, Vancouver, Winnipeg
Age
18 years and over
People
247 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT04269902
Phase 2Taking people
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Barrie, Saskatoon
Age
18 years and over
People
249 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Toronto
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Calgary, Montreal, Ottawa, Toronto
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Calgary, Edmonton, Montreal, Ottawa, Québec, St. John's, Toronto, Vancouver, Winnipeg
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
No phaseTaking people
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Where
Montreal, Oshawa, Ottawa, Saint John, Vancouver, Winnipeg
Age
18 years and over
People
247
Run by
Canadian Cancer Trials Group
See details and how to joinNCT05371808
Phase 1Taking people
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Where
Calgary, Ottawa, Toronto, Vancouver
Age
1 year and over
People
24
Run by
British Columbia Cancer Agency
See details and how to joinNCT06208735
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Fredericton, Montreal
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Brampton, Kelowna, Montreal, Ottawa, Rimouski, Victoria
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 3Taking people
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Where
Calgary, Halifax, Hamilton, Montreal, Québec, Toronto, Vancouver
Age
18 years to 18 years
People
420 worldwide
Run by
AstraZeneca
See details and how to joinNCT07509151
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Calgary, Edmonton, Québec, Toronto, Vancouver
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
No phaseTaking people
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Where
Vancouver
Age
19 years to 100 years
People
30
Run by
British Columbia Cancer Agency
See details and how to joinNCT06224309
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Calgary, Montreal, Toronto
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Where
Greenfield Park, Hamilton, London, Montreal, Ottawa, SaintJerome
Age
18 years and over
People
250 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Hamilton, Montreal, Québec, Sherbrooke, Victoria
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
No phaseTaking people
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Where
London
Age
6 years to 39 years
People
330 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT05702645
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Montreal, Québec, Winnipeg
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Halifax
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 1Taking people
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Where
Toronto
Age
18 years and over
People
19
Run by
University Health Network, Toronto
See details and how to joinNCT05963217
Phase 1Taking people
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Where
Toronto
Age
18 years and over
People
242 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT04260022
Phase 1/2Taking people
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Where
Ottawa, Vancouver, Winnipeg
Age
18 years to 75 years
People
60
Run by
Ottawa Hospital Research Institute
See details and how to joinNCT03765177
Phase 2Not yet taking people in Canada
Time Restricted Eating in Haematological Malignancies
Where
Victoria
Age
18 years to 85 years
People
75
Run by
British Columbia Cancer Agency
See details and how to joinNCT06862323